BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MLSC - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MLSC
X-ORIGINAL-URL:https://www.masslifesciences.com
X-WR-CALDESC:Events for MLSC
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210503T080000
DTEND;TZID=America/New_York:20210619T235900
DTSTAMP:20260509T105131
CREATED:20210409T185112Z
LAST-MODIFIED:20210409T185112Z
UID:13684-1620028800-1624147140@www.masslifesciences.com
SUMMARY:Foundations in Quality for the Life Sciences
DESCRIPTION:This course provides an insight into the mindset of Quality along with an overview the concepts\, principles and processes/activities involved in Quality Assurance\, Quality Control\, and Regulatory Compliance within the Life Sciences Industry. Emphasis will be placed on understanding the “business of Biotech; the remit of Global Regulatory Agencies and principles/processes for establishing and enforcing regulation and guidance; Quality management systems\, operations and compliance; Quality leadership; Quality Planning; and Careers in the Quality profession. Students will be exposed to a variety of industry experts during the course. Emphasis will also be placed on current Good Manufacturing Practices\, Good Laboratory Practices and Good Clinical Practices. Students will gain a practical knowledge of Quality as a scientific discipline.
URL:https://www.masslifesciences.com/event/foundations-in-quality-for-the-life-sciences/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210601
DTEND;VALUE=DATE:20210602
DTSTAMP:20260509T105131
CREATED:20210511T202612Z
LAST-MODIFIED:20210511T202612Z
UID:13845-1622505600-1622591999@www.masslifesciences.com
SUMMARY:Harvard Medical School Master of Bioethics
DESCRIPTION:The Harvard Master of Bioethics program is now offering a two-year\, part-time virtual option for mid-career students entering in the fall of 2021. The two-year\, part-time virtual option leverages our high-quality\, cutting edge bioethics curriculum with a focus on discussion-based and applied learning in a flexible online format that appeals to leaders in a wide range of disciplines at the intersection of health care\, law\, academia\, and public health. \nThe program includes online required and elective coursework and opportunities to build your Harvard bioethics network virtually. \nFinal Application Deadline: June 1
URL:https://www.masslifesciences.com/event/harvard-medical-school-master-of-bioethics/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210601T153000
DTEND;TZID=America/New_York:20210621T173000
DTSTAMP:20260509T105131
CREATED:20210511T202231Z
LAST-MODIFIED:20210511T202231Z
UID:13879-1622561400-1624296600@www.masslifesciences.com
SUMMARY:Biotechnology Project Management (June 2021)
DESCRIPTION:Biotechnology Project Management examines critical aspects of project management\, including an overview of the drug development process and regulatory agencies. Participants learn to use tools and strategies for working in a team environment to analyze risk\, allocate resources\, track projects\, resolve conflicts\, make decisions\, and manage teams. Experiential learning labs\, class participation\, and real-world examples are used to maximize educational impact. \nSchedule\nTuesday\, June 1st\, 2021 at 3:30-6:30 PM EST\nWednesday\, June 2nd\, 2021 at 3:30-5:30 PM EST\nFriday\, June 4th\, 2021 at 3:30-5:30 PM EST\nMonday\, June 7th\, 2021 at 3:30-5:30 PM EST\nWednesday\, June 9th\, 2021 at 3:30-5:30 PM EST\nFriday\, June 11th\, 2021 at 3:30-5:30 PM EST\nMonday\, June 14th\, 2021 at 3:30-5:30 PM EST\nWednesday\, June 16th\, 2021 at 3:30-5:30 PM EST\nFriday\, June 18th\, 2021 at 3:30-5:30 PM EST\nMonday\, June 21st\, 2021 at 3:30-5:30 PM EST \nSmall Business Direct Access Program: Massachusetts companies with 100 employees or less may be eligible to take this course beginning in Fall 2021 at no cost. You can apply for the program by following the directions below. Note\, your application should be submitted at least four (4) weeks before your intended start date of training. \nTo see if your company is already registered through the Small Business Direct Access Program\, you can check the list of eligible businesses by clicking “List of eligible businesses” on the page here.\nPlease note\, the approval process can take 2-4 weeks. The application does not save progress\, so it is important to have all of the necessary required documents\, referenced in Step 2\, in advance of filling out and submitting your application here. If your company is not listed\, you can register using the form at the bottom of the page.\nOnce your company is approved\, the Commonwealth Corporation will notify the contact person by email and you will be added to the List of eligible businesses.\nOnce approved\, please email courses@massbioed.orgwith the name of the employee(s) who wish to register\, and we will add them to the course roster for the next available course.\nFurther directions on how to enroll employees through the Small Business Direct Access Program can be found here.\nTo stay updated on the Direct Access Program and other course announcements\, you can sign up for our newsletter here. \nInstructor\nNazma M. Rosado\, MAOL\, PMP\, CMQ/OE\nPresident & Principal\, Transformative Consulting \nNazma Rosado\, President & Principal at Transformative Consulting\, Inc. has over 25 years of experience in the Biopharma industry and has worked on clinical trial phases I-IV with experience in all aspects of study management including study start-up\, conduct and close-out. She has worked in Data Management\, Clinical Operations\, Regulatory Affairs and Quality Assurance\, Project Management\, Process Optimization\, Learning & Development\, Change Management\, and\, Organizational Design & Development for major and mid-sized pharmaceutical and small biotech companies\, as well as for a contract research organization (CRO)\, and consulting companies. She has worked in a highly regulated industry and understands compliance needs. Nazma has focused on the Organizational Leadership and Development aspects of the companies she has worked for\, and has been instrumental in designing and implementing solutions to better the workplace for staff and management. She works with senior leaders to help change behaviors that shape the company’s culture and increase employee engagement. Nazma has a passion for people and a strong desire to make the workplace more diverse\, engaging\, and productive by choice. \nNazma has a B.A. in Neuroscience and a B.A. in Psychology from Colgate University and a M.A. in Organizational Leadership from Gonzaga University. She has 33 credits towards her Master in Public Health at the University of Connecticut. In addition to her traditional education\, Nazma has earned many professional certifications including the following: Project Management Professional (PMP)\, Six Sigma Green Belt (6σ)\, Certified Professional in Learning & Performance (CPLP) and Certified Manager of Quality/ Organizational Excellence (CMQ/OE). She holds many certifications in Change Management as well\, including AMPG and Prosci certifications. Nazma was involved with TransCelerate Biopharma\, Inc. for 2 years and served as a Co-Lead for the Change Management Council and as the Change Champion for Astellas Pharma. She also served as a member of the Healthcare Businesswoman’s Association (HBA) Mid-Atlantic Region board (Programming Co-Chair). Nazma currently serves on the Board of the Organization Development Network and is the Chair of the Marketing & Communications Committee.
URL:https://www.masslifesciences.com/event/biotechnology-project-management-june-2021/
LOCATION:Online\, online
ORGANIZER;CN="MassBioEd":MAILTO:communications@massbioed.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210602T100000
DTEND;TZID=America/New_York:20210602T150000
DTSTAMP:20260509T105131
CREATED:20210514T152428Z
LAST-MODIFIED:20210514T152428Z
UID:13944-1622628000-1622646000@www.masslifesciences.com
SUMMARY:MassBioEd's 6th Annual Life Sciences Workforce Conference
DESCRIPTION:The Life Sciences Workforce Conference is uniquely devoted to bringing together the life sciences industry and academia to discuss training of the next generation of leaders. The event provides an opportunity for industry professionals and academicians to hear from each other\, and to hold meaningful conversations about education and training as well as career exploration and readiness. The 2021 Life Sciences Workforce Conference will be both informative and highly interactive with built in time for discussing topics together and developing solutions!
URL:https://www.masslifesciences.com/event/massbioeds-6th-annual-life-sciences-workforce-conference/
LOCATION:Online\, online
ORGANIZER;CN="MassBioEd":MAILTO:communications@massbioed.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210602T100000
DTEND;TZID=America/New_York:20210602T150000
DTSTAMP:20260509T105131
CREATED:20210527T144259Z
LAST-MODIFIED:20210527T144259Z
UID:13947-1622628000-1622646000@www.masslifesciences.com
SUMMARY:MassBioEd's 2021 Life Sciences Workforce Conference
DESCRIPTION:The Life Sciences Workforce Conference is uniquely devoted to bringing together the life sciences industry and academia to discuss training of the next generation of leaders. The event provides an opportunity for industry professionals and academicians to hear from each other\, and to hold meaningful conversations about education and training as well as career exploration and readiness. The 2021 Life Sciences Workforce Conference will be both informative and highly interactive with built in time for discussing topics together and developing solutions! \nAgenda\n10:00am – 10:15am \nWelcome Remarks \nSunny Schwartz\, Executive Director\, MassBioEd \n10:15am – 11:00am \nMassBioEd’s 2021 Life Sciences Employment Outlook and Q&A \nKarla Talanian\, Director of Talent and Workforce Development\, MassBioEd \n11:00am – 12:00pm \nExpanding the Pool of Workers: Specific Workforce Challenge Areas \nPresentations and Facilitated Group Discussions: \nInspiring College Students to Pursue STEM Careers\nEnding Talent Wars: Growing the Clinical Research Talent Pool\nBig Tech vs. Biotech: Winning the Competition for Talent in Data Science\nHiring and Securing Foreign-Born Talent\nMeeting the Growing Demand for Biomanufacturing Talent\nmore to come! \n12:00pm – 1:00pm Open Networking & Lunch Break\n1:00pm – 1:55pm \nFlexibility and Mobility of the New Workforce and Q&A \nMark Bamforth\, Chief Executive Officer\, Arranta Bio\nJacquelyn Fouse\, Chief Executive Officer\, Agios Pharmaceuticals\nJohn Maraganore\, Chief Executive Officer\, Alnylam Pharmaceuticals\nModerated by Sunny Schwartz\, Executive Director\, MassBioEd \n1:55pm – 2:50pm \nExpanding Landscape of the Life Sciences Across Massachusetts and Q&A \nOpening Remarks by Christopher Murphy\, Vice President and General Manager\, Viral Vector Services\, Thermo Fisher Scientific and Chair of the MassBioEd Board of Directors\nRobert Coughlin\, Managing Director – Life Sciences\, JLL\nBenjamin Bradford\, Vice President of Membership and Economic Development\, MassBio\nModerated by Rita Smith\, Director\, Business Human Resources\, AbbVie \n2:50pm – 3:00pm Conclusion\nFeatured Topics \nMassBioEd’s 2021 Life Sciences Employment Outlook: Hot off the press\, the report will be released in conjunction with the conference and will cover the effects of 2020 on the life sciences workforce – including COVID-19 and calls for racial equity – as well as historical trends in overall employment and hiring demand. \nExpanding the Pool of Workers: Everyone agrees that supply of talent is not keeping up with the demand\, and traditional ways of recruitment are not adequate. \nHow do we grow the pool of qualified job seekers?\nHow do college students view the viability and attractiveness of a career in biopharma relative to other fields?\nWhat new innovations will ensure an inclusive culture as the workforce is diversified? \nFlexibility and Mobility of the New Workforce: 2020 proved beyond a doubt that the traditional workplace and structure are not essential to a highly productive workforce. Companies are already hiring worldwide for certain positions with the intent of never bringing newcomers into a traditional work environment. \nWhat should the future workforce look like?\nHow will the new workforce structure affect Massachusetts and the life sciences industry? \nExpanding Landscape of the Life Sciences Across Massachusetts: Many companies have announced plans to construct new offices\, labs\, and especially biomanufacturing facilities in Massachusetts over the past year. Our talent supply was already inadequate for the demand. \nWho will work in these new jobs?\nHow will Massachusetts meet this new level of demand?\nAre new training mechanisms needed?
URL:https://www.masslifesciences.com/event/massbioeds-2021-life-sciences-workforce-conference/
LOCATION:Online\, online
ORGANIZER;CN="MassBioEd":MAILTO:communications@massbioed.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210602T120000
DTEND;TZID=America/New_York:20210602T133000
DTSTAMP:20260509T105131
CREATED:20210510T200054Z
LAST-MODIFIED:20210510T200054Z
UID:13886-1622635200-1622640600@www.masslifesciences.com
SUMMARY:Clinical Trial Program Series - MEDICAL PRODUCT DEVELOPMENT 101
DESCRIPTION:Overview \nThis program is a series of 3 panel discussions with industry and government partners\, focused on providing high-level insight into the clinical trial process. Each event will have its own specific focus while contributing to a sequential flow for the series. Experts from varying backgrounds have been selected for each discussion to help provide a more robust and complete overview of key considerations and event topics for each discussion.\nGoal \nThis program aims to provide early-stage startups\, stakeholders\, and others\, with expert insight and knowledge into the clinical trial process. From attending these discussions\, attendees should have a better understanding of clinical trials\, the necessary steps needed to develop a plan that will lead to successful study outcomes\, insight into key considerations for the process\, and a better understanding of what partners to engage with\, and when.\nAgenda \n12:00pm – 12:30pm: Opening Remarks \n12:05pm – 12:10pm: Panelist Introductions \n12:10pm – 1:10pm: Panel Discussion \n1:10pm – 1:25pm: Q&A \n1:25pm – 1:30pm: Closing Remarks\nTopics \nClinical Trial Basics – Understanding your product\, Designing Your Study\, Regulatory Requirements and EC/IRB and Informed Consent\nSite selection\nMedical Device vs. Therapeutic\nDeveloping an MVP and manufacturing a product for studies\nThe importance of strategy and planning \nPanelists \nBarry Sands – President & Founder\, RQMIS\, Inc. \nRQMIS President and Founder\, Barry E. Sands\, is a Biomedical Engineer (with a chemical engineering specialization) by trade with a passion for helping medical companies get their products to market. Barry has seven years’ experience as a Biomedical Engineer and Sr. Scientific Reviewer at FDA/CDRH/ODE and FDA’s Boston District. This government experience was followed with seventeen years in midlevel and executive management positions in small start-up and large multinational medical device companies. Market responsibilities included United States (including Puerto Rico)\, European Union\, South America\, Middle East\, Canada\, Japan and South Korea. \nHe has provided companies with regulatory and clinical strategic advice on bringing novel technologies for both the pediatric and adult populations specially to the United States and EU markets. The devices involved have included wearable devices\, human tissue\, combination products\, electromechanical\, PPE\, ultrasonic imaging and PACS products. He has worked on various innovative medical devices including writing an FDA Presubmission for an electromechanical medical device with software that was used to diagnose radiation exposure. Barry was the primary author of the IDE for an electromechanical device with software that used irreversible electroporation used to treat Stage III Pancreatic Cancer. \nBarry has managed data management services designed to make the process of designing\, collecting\, reconciling and reviewing clinical research data more efficient and reliable. He has extensive knowledge of clinical data and biostatistics\, thus leading groups to make the use of EDC technology and the surrounding processes work to ensure the integrity of each data set. By minimizing the risks associated with EDC and clinical data management\, clean and accurate clinical research data is captured while meeting aggressive key project deadlines. Being for the sponsors\, less training time for each project and more time performing efficient tests. Within this point\, the role played by Barry is key to the successful planning and execution of a development program. \nHe has worked with different companies throughout his career path to accompany new projects developments\, in conjunction with the steps for having the facilities aligned to the worldwide regulations\, especially in QMS\, Manufacturing Operations & SupplyManagement. During these projects\, Barry is deeply involved in all the manufacturing activities\, managing and training people under the latest regulations. His QMS/Manufacturing experience has included the establishment of clean rooms for the packaging of sterile implants. Products manufactured in the QMS that Barry has designed/managed have included a wide range of complexity from soft bracing products to sterile active implantable products. \nBarry is currently serving as the Executive Regulatory Manager for a client that is working on developing an electronically-determined test for stroke that employs both AI and Machine Learning algorithms. In this role he guides all regulatory and quality decisions in related to product development. RQMIS is also currently developing a regulatory strategy and Presubmission to the FDA for a company developing a wearable patch that will detect biomarkers in a patient’s sweat using AI and machine learning technology. Similarly\, our team is working on generating a regulatory strategy for certification and testing standards required for masks for the FDA\, European NB and MHRA. \nHe is the CAPCaT reviewer responsible for reviewing/grading medical device grant applications to support development\, deployment\, and testing of promising “late-stage” point of care technologies that can be rapidly deployed to enhance the diagnosis\, monitoring\, management\, and/or treatment of heart\, lung\, blood or sleep disorders (NHLBI)\, with an additional interest in projects that incorporate complementary and integrative health approaches (NCCIH). \nBarry has managed FDA inspections in R&D facilities (including clinical study files) and manufacturing facilities located in the United States\, Germany and Japan. These inspections have included Level 1 (Abbreviated)\, Level 2 (Comprehensive)\, Level 3 (Compliance Follow‐up)\, For Cause\, Sterilization processes\, MDR/MedWatch\, Corrections and Removals Practices\, and Biomonitoring/Good Clinical Practices. Barry has designed/implemented corrective actions to resolve 483s\, Warning Letters\, and import detentions. \nAnn Han – Clinical Research Navigator\, University of Massachusetts Medical School \nAnn Han is the Clinical Research Navigator at UMass Medical where she works to connect researchers to resources to improve the efficiency and quality of clinical research. She facilitates clinical trial site selection activities and assists with clinical trial feasibility and recruitment and retention. She is a UMass CCTS Point of Contact for the Trial Innovation Network and a member of the CCTS and COVID research protocol review committees. She received her Master of Science in Health Services Research from Boston University and has over 15 years’ experience in clinical research. \nMelinda Hamer – Director of the Clinical Trials Center\, Walter Reed Army Institute of Research \nMelinda Morton Hamer MD\, MPH was the Director of the Clinical Trials Center at the Walter Reed Army Institute of Research from 2017-2021\, and is currently detailed to the Department of Health and Human Services\, Biomedical Advanced Research and Development Authority as a Senior Medical Advisor. She has served as a principal and associate investigator for more than 20 FDA regulated and other clinical trials\, to include multiple first-in-human vaccine trials\, and the largest in history controlled human malaria challenge trial\, and managed an annual budget of more than $10 million. She was principal investigator of the recently completed first-in-human trial of a novel Marburg virus vaccine\, in collaboration with the NIH’s Vaccine Research Center\, and served as an investigator on multiple COVID-19 related clinical trials. She is a U.S. Army flight surgeon and board-certified emergency physician\, and an Associate Professor in the Department of Military and Emergency \nMedicine at the Uniformed Services University of the Health Sciences in Bethesda\, Maryland. She also holds a part-time appointment as an Assistant Professor in the Department of Emergency Medicine at the George Washington University Department of Emergency Medicine. Dr. Hamer is also the co-author of official U.S. Government and Institute of Medicine reports on health care reconstruction efforts in Iraq\, and has over 40 peer-reviewed publications as well as dozens of national abstract presentations and other reports. \nMeg Johnson – Senior Manager of Clinical Research Compliance\, University of Massachusetts Medical School \nMeg Johnson has overseen the Office of Clinical Research for UMass Medical for the past 8 years. Prior to UMass Medical she worked in IRB Operations and Research for Harvard Medical School and Ohio State University. Meg received her BS in Health Policy and Administration from Penn State and her JD in Law from Ohio State University. \nGustavo Cipolla – Associate Director of Preclinical at Ethicon\, Johnson & Johnson \nInterventionalist & Scientist D.V.M. with extensive experience and expertise in the areas of preclinical research\, operation of preclinical research labs\, IACUC\, physician training\, FDA submissions and GLP compliance. Excellent track record in developing and implementing target specific preclinical research studies. Proven adaptation to different working environments (academic institutions\, start ups\, established corporations and contract research organizations) \nSpecialties: Operations\, Execution\, Compliance\, IACUC\, GLP \nModerator: Eric Claude – Vice President of Product Development\, MPR Associates\, Inc. \nEric Claude is the Vice President of MPR’s Health and Life Science practice. Mr. Claude has a background in engineering and a broad systems perspective in product design. With more than 25 years in the medtech industry\, Mr. Claude’s leadership and experience helps teams navigate the complex challenges in developing and commercializing breakthrough products. He has a passion for developing high performance multi-disciplinary teams and a focus on optimizing the new product development process to best manage risk and minimize time to market. MPR’s clients\, including companies large and small\, rely on Mr. Claude to be a valued senior advisor and executive sponsor for critical projects.
URL:https://www.masslifesciences.com/event/clinical-trial-program-series-medical-product-development-101/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210602T123000
DTEND;TZID=America/New_York:20210604T150000
DTSTAMP:20260509T105131
CREATED:20210511T202701Z
LAST-MODIFIED:20210511T202701Z
UID:13878-1622637000-1622818800@www.masslifesciences.com
SUMMARY:The Business Of Biotech 101
DESCRIPTION:Member Rate applies for MassBio Member Company\, Other State Bioscience Association Member Company\, MassCONNECT Company\, or Unemployed Individual\nBy registering for this course\, you are eligible to receive a 10% discount applied to your registration of Business of Biotech 201. Contact courses@massbioed.org to obtain the coupon code to enter when checking out. \nDescription\nBusiness of Biotech 101 explores the business considerations that drive company strategies. Students will be provided with foundational information about the BioPharma industry and regulation via instruction\, storytelling\, and breakout group discussions. Industry ethics will be discussed\, with emphasis on historical precedents. The course touches on topics such as market share\, phases of development\, patient population\, and safety profile. A high-level overview of Research and Development\, including pre-clinical through market approval will also reviewed. \nSchedule\nTuesday\, June 1st\, 2021 12:30-3:00 PM EST\nWednesday\, June 2nd\, 2021 12:30-3:00 PM EST\nFriday\, June 4th\, 2021 12:30-3:00 PM EST\nAgenda\nSession 1:\nOrigins of the Biotech Industry: a Brief History\nAddressing Unmet Medical Need\nBiotechnology techniques used for therapeutics development\nBiotech Entrepreneurship\nBusiness Models of the Sector and Industries within \nSession 2:\nPreclinical\nClinical Development\nCreating Barriers to Entry: Market Exclusivity \nSession 3\nPatents\nEarly Stage Financing \nInstructor\nJohn Tagliamonte\nChief Executive Officer\, Mellitus \nJohn Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development\, finance\, commercial and business operations\, strategic planning\, finance and legal functions with established and emerging public and private life sciences companies. As the first Entrepreneur-in-Residence with MassBio\, he was responsible for forward-looking program content across the organization\, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx\, Fractal\, MarkTx\, PhagePro and Tantu. Previously he led business development at Juniper\, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics\, ImmunoGen and Johnson & Johnson\, as well as venture investing with Safeguard. He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad. Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.
URL:https://www.masslifesciences.com/event/the-business-of-biotech-101/
LOCATION:Online\, online
ORGANIZER;CN="MassBioEd":MAILTO:communications@massbioed.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210603T120000
DTEND;TZID=America/New_York:20210603T123000
DTSTAMP:20260509T105131
CREATED:20210527T144208Z
LAST-MODIFIED:20210527T144208Z
UID:13951-1622721600-1622723400@www.masslifesciences.com
SUMMARY:AI and the Future of Breast Cancer Detection and Risk Prediction
DESCRIPTION:In this webinar\, Dr. Constance Lehman\, Professor of Radiology at Harvard Medical School and head of Breast Imaging at Massachusetts General Hospital will explore progress in applying AI to improve prediction of future risk of breast cancer based on mammography alone\, including validation trials in multi-ethnic populations. These advances will be discussed in the context of the broader goal to deliver more precise\, more personalized breast cancer detection\, diagnosis and treatment.
URL:https://www.masslifesciences.com/event/ai-and-the-future-of-breast-cancer-detection-and-risk-prediction/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210607T090000
DTEND;TZID=America/New_York:20210611T111500
DTSTAMP:20260509T105131
CREATED:20210510T200959Z
LAST-MODIFIED:20210510T200959Z
UID:13880-1623056400-1623410100@www.masslifesciences.com
SUMMARY:Science of Biotech 101 (June 2021)
DESCRIPTION:Member Rate applies for MassBio Member Company\, Other State Bioscience Association Member Company\, MassCONNECT Company\, or Unemployed Individual \nDescription\nScience of Biotech 101 is designed for the non-scientist. The class acts as a survey of the basic biological processes that are foundational to the biopharma and life sciences industry. Participants will apply their new understanding of basic cell and molecular biology to the work of life sciences companies that research and develop therapies and products to improve lives\, enhance agriculture\, and decrease the dependence on fossil fuels. \nSchedule\nMonday\, June 7th\, 2021 9:00-11:30 AM EST\nWednesday\, June 9th\, 2021 9:00-11:30 AM EST\nFriday\, June 11th\, 2021 9:00-11:30 AM EST \nAgenda\nSession 1: Introductions Industry Overview The Raw Materials of Biotechnology: Protein and Cells Industry Applications: The Raw Materials of Biotechnology: DNA \nSession 2: Molecular Biology: From DNA to Protein Genetics: Chromosomes\, Genes and Genomes Industry Applications \nSession 3: Genetic Engineering The Immune System Industry Applications: Mitigating Disease \nInstructor\nKelly Conn\, PhD\nAssociate Teaching Professor\, Northeastern University\nDr. Kelly J. Conn is a Teaching Professor within the Graduate School of Education at Northeastern University. Dr. Conn earned her BS in Cell Biology at the University of Kansas and her Ph.D. from Boston University School of Medicine. After completing post-doctoral training in Neuroscience\, Dr. Conn ran a Parkinson’s research laboratory for several years as an Assistant Research Professor at Boston University. Dr. Conn joined Northeastern University in 2010 where she works to support STEM education through her work within the Doctor of Education program and Northeastern University’s Network for Experiential Teaching and Learning—NExT. Most recently\, Dr. Conn has designed and oversees the curriculum for a Graduate Certificate in Experiential Teaching and Learning and serves as Faculty Lead of the Learning and Instruction MEd program.
URL:https://www.masslifesciences.com/event/science-of-biotech-101-june-2021/
LOCATION:Online\, online
ORGANIZER;CN="MassBioEd":MAILTO:communications@massbioed.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210609T120000
DTEND;TZID=America/New_York:20210609T133000
DTSTAMP:20260509T105131
CREATED:20210510T195954Z
LAST-MODIFIED:20210510T195954Z
UID:13887-1623240000-1623245400@www.masslifesciences.com
SUMMARY:Clinical Trial Program Series - INVESTOR & FINANCIAL STRATEGY
DESCRIPTION:Overview \nThis program is a series of 3 panel discussions with industry and government partners\, focused on providing high-level insight into the clinical trial process. Each event will have its own specific focus while contributing to a sequential flow for the series. Experts from varying backgrounds have been selected for each discussion to help provide a more robust and complete overview of key considerations and event topics for each discussion.\nGoal \nThis program aims to provide early-stage startups\, stakeholders\, and others\, with expert insight and knowledge into the clinical trial process. From attending these discussions\, attendees should have a better understanding of clinical trials\, the necessary steps needed to develop a plan that will lead to successful study outcomes\, insight into key considerations for the process\, and a better understanding of what partners to engage with\, and when.\nAgenda \n12:00pm – 12:30pm: Opening Remarks \n12:05pm – 12:10pm: Panelist Introductions \n12:10pm – 1:10pm: Panel Discussion \n1:10pm – 1:25pm: Q&A \n1:25pm – 1:30pm: Closing Remarks\nTopics \nClinical Trial Basics – Understanding your product\, Designing Your Study\, Regulatory Requirements and EC/IRB and Informed Consent\nSite selection\nMedical Device vs. Therapeutic\nDeveloping an MVP and manufacturing a product for studies\nThe importance of strategy and planning \nPanelists \nBarry Sands – President & Founder\, RQMIS\, Inc. \nRQMIS President and Founder\, Barry E. Sands\, is a Biomedical Engineer (with a chemical engineering specialization) by trade with a passion for helping medical companies get their products to market. Barry has seven years’ experience as a Biomedical Engineer and Sr. Scientific Reviewer at FDA/CDRH/ODE and FDA’s Boston District. This government experience was followed with seventeen years in midlevel and executive management positions in small start-up and large multinational medical device companies. Market responsibilities included United States (including Puerto Rico)\, European Union\, South America\, Middle East\, Canada\, Japan and South Korea. \nHe has provided companies with regulatory and clinical strategic advice on bringing novel technologies for both the pediatric and adult populations specially to the United States and EU markets. The devices involved have included wearable devices\, human tissue\, combination products\, electromechanical\, PPE\, ultrasonic imaging and PACS products. He has worked on various innovative medical devices including writing an FDA Presubmission for an electromechanical medical device with software that was used to diagnose radiation exposure. Barry was the primary author of the IDE for an electromechanical device with software that used irreversible electroporation used to treat Stage III Pancreatic Cancer. \nBarry has managed data management services designed to make the process of designing\, collecting\, reconciling and reviewing clinical research data more efficient and reliable. He has extensive knowledge of clinical data and biostatistics\, thus leading groups to make the use of EDC technology and the surrounding processes work to ensure the integrity of each data set. By minimizing the risks associated with EDC and clinical data management\, clean and accurate clinical research data is captured while meeting aggressive key project deadlines. Being for the sponsors\, less training time for each project and more time performing efficient tests. Within this point\, the role played by Barry is key to the successful planning and execution of a development program. \nHe has worked with different companies throughout his career path to accompany new projects developments\, in conjunction with the steps for having the facilities aligned to the worldwide regulations\, especially in QMS\, Manufacturing Operations & SupplyManagement. During these projects\, Barry is deeply involved in all the manufacturing activities\, managing and training people under the latest regulations. His QMS/Manufacturing experience has included the establishment of clean rooms for the packaging of sterile implants. Products manufactured in the QMS that Barry has designed/managed have included a wide range of complexity from soft bracing products to sterile active implantable products. \nBarry is currently serving as the Executive Regulatory Manager for a client that is working on developing an electronically-determined test for stroke that employs both AI and Machine Learning algorithms. In this role he guides all regulatory and quality decisions in related to product development. RQMIS is also currently developing a regulatory strategy and Presubmission to the FDA for a company developing a wearable patch that will detect biomarkers in a patient’s sweat using AI and machine learning technology. Similarly\, our team is working on generating a regulatory strategy for certification and testing standards required for masks for the FDA\, European NB and MHRA. \nHe is the CAPCaT reviewer responsible for reviewing/grading medical device grant applications to support development\, deployment\, and testing of promising “late-stage” point of care technologies that can be rapidly deployed to enhance the diagnosis\, monitoring\, management\, and/or treatment of heart\, lung\, blood or sleep disorders (NHLBI)\, with an additional interest in projects that incorporate complementary and integrative health approaches (NCCIH). \nBarry has managed FDA inspections in R&D facilities (including clinical study files) and manufacturing facilities located in the United States\, Germany and Japan. These inspections have included Level 1 (Abbreviated)\, Level 2 (Comprehensive)\, Level 3 (Compliance Follow‐up)\, For Cause\, Sterilization processes\, MDR/MedWatch\, Corrections and Removals Practices\, and Biomonitoring/Good Clinical Practices. Barry has designed/implemented corrective actions to resolve 483s\, Warning Letters\, and import detentions. \nAnn Han – Clinical Research Navigator\, University of Massachusetts Medical School \nAnn Han is the Clinical Research Navigator at UMass Medical where she works to connect researchers to resources to improve the efficiency and quality of clinical research. She facilitates clinical trial site selection activities and assists with clinical trial feasibility and recruitment and retention. She is a UMass CCTS Point of Contact for the Trial Innovation Network and a member of the CCTS and COVID research protocol review committees. She received her Master of Science in Health Services Research from Boston University and has over 15 years’ experience in clinical research. \nMelinda Hamer – Director of the Clinical Trials Center\, Walter Reed Army Institute of Research \nMelinda Morton Hamer MD\, MPH was the Director of the Clinical Trials Center at the Walter Reed Army Institute of Research from 2017-2021\, and is currently detailed to the Department of Health and Human Services\, Biomedical Advanced Research and Development Authority as a Senior Medical Advisor. She has served as a principal and associate investigator for more than 20 FDA regulated and other clinical trials\, to include multiple first-in-human vaccine trials\, and the largest in history controlled human malaria challenge trial\, and managed an annual budget of more than $10 million. She was principal investigator of the recently completed first-in-human trial of a novel Marburg virus vaccine\, in collaboration with the NIH’s Vaccine Research Center\, and served as an investigator on multiple COVID-19 related clinical trials. She is a U.S. Army flight surgeon and board-certified emergency physician\, and an Associate Professor in the Department of Military and Emergency \nMedicine at the Uniformed Services University of the Health Sciences in Bethesda\, Maryland. She also holds a part-time appointment as an Assistant Professor in the Department of Emergency Medicine at the George Washington University Department of Emergency Medicine. Dr. Hamer is also the co-author of official U.S. Government and Institute of Medicine reports on health care reconstruction efforts in Iraq\, and has over 40 peer-reviewed publications as well as dozens of national abstract presentations and other reports. \nMeg Johnson – Senior Manager of Clinical Research Compliance\, University of Massachusetts Medical School \nMeg Johnson has overseen the Office of Clinical Research for UMass Medical for the past 8 years. Prior to UMass Medical she worked in IRB Operations and Research for Harvard Medical School and Ohio State University. Meg received her BS in Health Policy and Administration from Penn State and her JD in Law from Ohio State University. \nGustavo Cipolla – Associate Director of Preclinical at Ethicon\, Johnson & Johnson \nInterventionalist & Scientist D.V.M. with extensive experience and expertise in the areas of preclinical research\, operation of preclinical research labs\, IACUC\, physician training\, FDA submissions and GLP compliance. Excellent track record in developing and implementing target specific preclinical research studies. Proven adaptation to different working environments (academic institutions\, start ups\, established corporations and contract research organizations) \nSpecialties: Operations\, Execution\, Compliance\, IACUC\, GLP \nModerator: Eric Claude – Vice President of Product Development\, MPR Associates\, Inc. \nEric Claude is the Vice President of MPR’s Health and Life Science practice. Mr. Claude has a background in engineering and a broad systems perspective in product design. With more than 25 years in the medtech industry\, Mr. Claude’s leadership and experience helps teams navigate the complex challenges in developing and commercializing breakthrough products. He has a passion for developing high performance multi-disciplinary teams and a focus on optimizing the new product development process to best manage risk and minimize time to market. MPR’s clients\, including companies large and small\, rely on Mr. Claude to be a valued senior advisor and executive sponsor for critical projects.
URL:https://www.masslifesciences.com/event/clinical-trial-program-series-investor-financial-strategy/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210609T143000
DTEND;TZID=America/New_York:20210609T153000
DTSTAMP:20260509T105131
CREATED:20210527T144321Z
LAST-MODIFIED:20210527T144630Z
UID:13941-1623249000-1623252600@www.masslifesciences.com
SUMMARY:Small Business Resources and SBIR/STTR Funding to Drive Commercialization in Translational Science
DESCRIPTION:Join the National Center for Advancing Translational Sciences (NCATS) in collaboration with University of Massachusetts Medical School on Wednesday\, June 9\, 2021\, for a webinar to learn about the Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) programs for researchers and entrepreneurs in translational science. \nNCATS offers non-dilutive funding and resources to help small businesses advance and commercialize promising translational biotech and life sciences research technologies. If you are a researcher in these fields and are interested in bringing your innovations to market you may be eligible to apply to the NCATS SBIR and STTR programs. \nRegister now to join the webinar\, Small Business Resources and SBIR/STTR Funding to Drive Commercialization in Translational Science on Wednesday\, June 9\, 2021\, 2:30 – 3:30 p.m. ET \nFeatured Speakers\nLili M. Portilla\, M.P.A.\nDirector\, Office of Strategic Alliances\nNational Center for Advancing Translational Sciences\nNational Institutes of Health\nNathaniel Hafer\, Ph.D.\nDirector of Operations\nUMass Center for Clinical and Translational Science (UMCCTS)\nUniversity of Massachusetts Medical School \nQuestions?\nTo arrange a one-on-one meeting to discuss your project ideas and related questions\, please email the NCATS Office of Strategic Alliances at NCATS-SBIRSTTR@mail.nih.gov and include a non-confidential executive summary describing your SBIR/STTR proposal with any specific aims you intend to address within your application. \nConnect with us! Follow us on Twitter and LinkedIn. Use #NCATSsbir and join the online conversation. \nThe webinar will feature:\n• An overview of the SBIR and STTR programs and benefits of funding\n• Key NCATS focus areas to advance clinical research and translational sciences\n• Tips for submitting a successful application\n• Upcoming opportunities and deadlines\n• Other resources and programs\, including NCATS’ Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs) programs \nWho Should Attend?\nIndividuals from the following groups are encouraged to attend:\n• Small biotech and/or life sciences technology businesses\n• Academic entrepreneurs\n• Technology transfer organizations\n• Entrepreneurs from women-owned and socially and economically disadvantaged (8a) small businesses. \nRegister Now \nAbout NCATS\nNCATS works to transform the translational science process so that new prevention\, detection and treatment technologies can be delivered to patients faster. Through its SBIR and STTR programs\, NCATS fosters small business participation in research and development (R&D) as well as private-sector technology commercialization. These programs are engines of innovation\, offering grants\, contracts and technical assistance to small businesses and research organizations. \nAbout University of Massachusetts Medical School\nThe University of Massachusetts Medical School (UMMS) is the commonwealth’s first and only public academic health sciences center. Their mission is to advance the health and wellness of our diverse communities throughout Massachusetts and across the world by leading and innovating in education\, research\, health care delivery and public service. \nNCATS’ SBIR and STTR programs are engines of innovation for developing and commercializing tools\, technologies and intervention platforms to support the creation of new therapeutics and diagnostics. SBIR and STTR are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.
URL:https://www.masslifesciences.com/event/small-business-resources-and-sbir-sttr-funding-to-drive-commercialization-in-translational-science/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210615T110000
DTEND;TZID=America/New_York:20210624T140000
DTSTAMP:20260509T105131
CREATED:20210409T185029Z
LAST-MODIFIED:20210409T185029Z
UID:13686-1623754800-1624543200@www.masslifesciences.com
SUMMARY:Designing and Implementing AI Solutions for Health Care
DESCRIPTION:Applications of artificial intelligence in health care are expanding rapidly. Despite its great long-term potential\, risks and challenges remain for both AI developers and their partners in health care\, the life sciences industry and digital health. \nThis program will allow leaders across the ecosystem to gain insights into what it takes to successful utilize AI in the unique cultural\, economic and regulatory context of health care. Interactive sessions will address technical concepts as well as real-world implementation\, with examples drawn from health care delivery/operations and drug development. \nThe curriculum will feature a combination of live virtual class sessions\, small group application exercises\, pre-work and vigorous discussions. Upon completion of the program\, participants will be able to immediately apply insights gained to the fast-moving and complex health care sector. A certificate of completion will be provided.
URL:https://www.masslifesciences.com/event/designing-and-implementing-ai-solutions-for-health-care/
LOCATION:Harvard Medical School\, 25 Shattuck St\, Boston\, 02115\, United States
ORGANIZER;CN="Harvard Medical School External Education":MAILTO:sqil@hms.harvard.edu
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210615T120000
DTEND;TZID=America/New_York:20210615T133000
DTSTAMP:20260509T105131
CREATED:20210510T195846Z
LAST-MODIFIED:20210510T195846Z
UID:13888-1623758400-1623763800@www.masslifesciences.com
SUMMARY:Clinical Trial Program Series - KEY CONSIDERATIONS & BEST PRACTICES
DESCRIPTION:Overview \nThis program is a series of 3 panel discussions with industry and government partners\, focused on providing high-level insight into the clinical trial process. Each event will have its own specific focus while contributing to a sequential flow for the series. Experts from varying backgrounds have been selected for each discussion to help provide a more robust and complete overview of key considerations and event topics for each discussion.\nGoal \nThis program aims to provide early-stage startups\, stakeholders\, and others\, with expert insight and knowledge into the clinical trial process. From attending these discussions\, attendees should have a better understanding of clinical trials\, the necessary steps needed to develop a plan that will lead to successful study outcomes\, insight into key considerations for the process\, and a better understanding of what partners to engage with\, and when.\nAgenda \n12:00pm – 12:30pm: Opening Remarks \n12:05pm – 12:10pm: Panelist Introductions \n12:10pm – 1:10pm: Panel Discussion \n1:10pm – 1:25pm: Q&A \n1:25pm – 1:30pm: Closing Remarks\nTopics \nClinical Trial Basics – Understanding your product\, Designing Your Study\, Regulatory Requirements and EC/IRB and Informed Consent\nSite selection\nMedical Device vs. Therapeutic\nDeveloping an MVP and manufacturing a product for studies\nThe importance of strategy and planning \nPanelists \nBarry Sands – President & Founder\, RQMIS\, Inc. \nRQMIS President and Founder\, Barry E. Sands\, is a Biomedical Engineer (with a chemical engineering specialization) by trade with a passion for helping medical companies get their products to market. Barry has seven years’ experience as a Biomedical Engineer and Sr. Scientific Reviewer at FDA/CDRH/ODE and FDA’s Boston District. This government experience was followed with seventeen years in midlevel and executive management positions in small start-up and large multinational medical device companies. Market responsibilities included United States (including Puerto Rico)\, European Union\, South America\, Middle East\, Canada\, Japan and South Korea. \nHe has provided companies with regulatory and clinical strategic advice on bringing novel technologies for both the pediatric and adult populations specially to the United States and EU markets. The devices involved have included wearable devices\, human tissue\, combination products\, electromechanical\, PPE\, ultrasonic imaging and PACS products. He has worked on various innovative medical devices including writing an FDA Presubmission for an electromechanical medical device with software that was used to diagnose radiation exposure. Barry was the primary author of the IDE for an electromechanical device with software that used irreversible electroporation used to treat Stage III Pancreatic Cancer. \nBarry has managed data management services designed to make the process of designing\, collecting\, reconciling and reviewing clinical research data more efficient and reliable. He has extensive knowledge of clinical data and biostatistics\, thus leading groups to make the use of EDC technology and the surrounding processes work to ensure the integrity of each data set. By minimizing the risks associated with EDC and clinical data management\, clean and accurate clinical research data is captured while meeting aggressive key project deadlines. Being for the sponsors\, less training time for each project and more time performing efficient tests. Within this point\, the role played by Barry is key to the successful planning and execution of a development program. \nHe has worked with different companies throughout his career path to accompany new projects developments\, in conjunction with the steps for having the facilities aligned to the worldwide regulations\, especially in QMS\, Manufacturing Operations & SupplyManagement. During these projects\, Barry is deeply involved in all the manufacturing activities\, managing and training people under the latest regulations. His QMS/Manufacturing experience has included the establishment of clean rooms for the packaging of sterile implants. Products manufactured in the QMS that Barry has designed/managed have included a wide range of complexity from soft bracing products to sterile active implantable products. \nBarry is currently serving as the Executive Regulatory Manager for a client that is working on developing an electronically-determined test for stroke that employs both AI and Machine Learning algorithms. In this role he guides all regulatory and quality decisions in related to product development. RQMIS is also currently developing a regulatory strategy and Presubmission to the FDA for a company developing a wearable patch that will detect biomarkers in a patient’s sweat using AI and machine learning technology. Similarly\, our team is working on generating a regulatory strategy for certification and testing standards required for masks for the FDA\, European NB and MHRA. \nHe is the CAPCaT reviewer responsible for reviewing/grading medical device grant applications to support development\, deployment\, and testing of promising “late-stage” point of care technologies that can be rapidly deployed to enhance the diagnosis\, monitoring\, management\, and/or treatment of heart\, lung\, blood or sleep disorders (NHLBI)\, with an additional interest in projects that incorporate complementary and integrative health approaches (NCCIH). \nBarry has managed FDA inspections in R&D facilities (including clinical study files) and manufacturing facilities located in the United States\, Germany and Japan. These inspections have included Level 1 (Abbreviated)\, Level 2 (Comprehensive)\, Level 3 (Compliance Follow‐up)\, For Cause\, Sterilization processes\, MDR/MedWatch\, Corrections and Removals Practices\, and Biomonitoring/Good Clinical Practices. Barry has designed/implemented corrective actions to resolve 483s\, Warning Letters\, and import detentions. \nAnn Han – Clinical Research Navigator\, University of Massachusetts Medical School \nAnn Han is the Clinical Research Navigator at UMass Medical where she works to connect researchers to resources to improve the efficiency and quality of clinical research. She facilitates clinical trial site selection activities and assists with clinical trial feasibility and recruitment and retention. She is a UMass CCTS Point of Contact for the Trial Innovation Network and a member of the CCTS and COVID research protocol review committees. She received her Master of Science in Health Services Research from Boston University and has over 15 years’ experience in clinical research. \nMelinda Hamer – Director of the Clinical Trials Center\, Walter Reed Army Institute of Research \nMelinda Morton Hamer MD\, MPH was the Director of the Clinical Trials Center at the Walter Reed Army Institute of Research from 2017-2021\, and is currently detailed to the Department of Health and Human Services\, Biomedical Advanced Research and Development Authority as a Senior Medical Advisor. She has served as a principal and associate investigator for more than 20 FDA regulated and other clinical trials\, to include multiple first-in-human vaccine trials\, and the largest in history controlled human malaria challenge trial\, and managed an annual budget of more than $10 million. She was principal investigator of the recently completed first-in-human trial of a novel Marburg virus vaccine\, in collaboration with the NIH’s Vaccine Research Center\, and served as an investigator on multiple COVID-19 related clinical trials. She is a U.S. Army flight surgeon and board-certified emergency physician\, and an Associate Professor in the Department of Military and Emergency \nMedicine at the Uniformed Services University of the Health Sciences in Bethesda\, Maryland. She also holds a part-time appointment as an Assistant Professor in the Department of Emergency Medicine at the George Washington University Department of Emergency Medicine. Dr. Hamer is also the co-author of official U.S. Government and Institute of Medicine reports on health care reconstruction efforts in Iraq\, and has over 40 peer-reviewed publications as well as dozens of national abstract presentations and other reports. \nMeg Johnson – Senior Manager of Clinical Research Compliance\, University of Massachusetts Medical School \nMeg Johnson has overseen the Office of Clinical Research for UMass Medical for the past 8 years. Prior to UMass Medical she worked in IRB Operations and Research for Harvard Medical School and Ohio State University. Meg received her BS in Health Policy and Administration from Penn State and her JD in Law from Ohio State University. \nGustavo Cipolla – Associate Director of Preclinical at Ethicon\, Johnson & Johnson \nInterventionalist & Scientist D.V.M. with extensive experience and expertise in the areas of preclinical research\, operation of preclinical research labs\, IACUC\, physician training\, FDA submissions and GLP compliance. Excellent track record in developing and implementing target specific preclinical research studies. Proven adaptation to different working environments (academic institutions\, start ups\, established corporations and contract research organizations) \nSpecialties: Operations\, Execution\, Compliance\, IACUC\, GLP \nModerator: Eric Claude – Vice President of Product Development\, MPR Associates\, Inc. \nEric Claude is the Vice President of MPR’s Health and Life Science practice. Mr. Claude has a background in engineering and a broad systems perspective in product design. With more than 25 years in the medtech industry\, Mr. Claude’s leadership and experience helps teams navigate the complex challenges in developing and commercializing breakthrough products. He has a passion for developing high performance multi-disciplinary teams and a focus on optimizing the new product development process to best manage risk and minimize time to market. MPR’s clients\, including companies large and small\, rely on Mr. Claude to be a valued senior advisor and executive sponsor for critical projects.
URL:https://www.masslifesciences.com/event/clinical-trial-program-series-key-considerations-best-practices/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210616T130000
DTEND;TZID=America/New_York:20210616T140000
DTSTAMP:20260509T105131
CREATED:20210527T143939Z
LAST-MODIFIED:20210527T143939Z
UID:13972-1623848400-1623852000@www.masslifesciences.com
SUMMARY:LET'S TALK ABOUT: MODELING BEHAVIOR Examining DEI in Life Sciences
DESCRIPTION:One year ago\, the Death of George Floyd sparked a worldwide movement for racial equality and justice. There was an outcry of support from corporates and startups alike. There were press releases and social posts advocating for diversity\, equity\, inclusion—and industry-wide change. This month Let’s Talk About will examine how the life science industry has changed\, how companies have approached DEI initiatives\, and what start-ups can do to make their work culture inclusive.
URL:https://www.masslifesciences.com/event/lets-talk-about-modeling-behavior-examining-dei-in-life-sciences/
LOCATION:Online\, online
ORGANIZER;CN="LaunchBio":MAILTO:joan@launchbio.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210616T183000
DTEND;TZID=America/New_York:20210616T193000
DTSTAMP:20260509T105131
CREATED:20210409T184630Z
LAST-MODIFIED:20210409T184713Z
UID:13691-1623868200-1623871800@www.masslifesciences.com
SUMMARY:A Foot in Both Worlds
DESCRIPTION:The MIT Koch Institute Clinical Investigator program offers physician-scientists a unique opportunity to participate in cutting-edge cancer research while continuing their medical practice and provides Koch Institute researchers with a frontline view of challenges in cancer treatment. This roundtable discussion with past and present Clinical Investigators explores the relationship between laboratory benchwork and clinical translation and practice. \nFeatured Presenters: \nScott Floyd\, MD\, PhD\nGary Hock and Lyn Proctor Associate Professor of Radiation Oncology\, Duke University\nAssistant Research Professor in Pharmacology and Cancer Biology\, Duke University Cancer Center \nSalil Garg\, MD\, PhD\nCharles W. (1955) and Jennifer C. Johnson Clinical Investigator\, Koch Institute\nPathologist\, Massachusetts General Hospital \nHojun Li\, MD\, PhD\nCharles W. (1955) and Jennifer C. Johnson Clinical Investigator\, Koch Institute\nAttending Physician\, Dana Farber/Boston Children’s Hospital Cancer and Blood Disorders Center \nAlice Tsang Shaw\, MD\, PhD\nGlobal Head of Translational Clinical Oncology\, Novartis\nAttending Physician\, Center for Thoracic Cancers\, Massachusetts General Hospital \nModerated by Michael B. Yaffe\, MD\, PhD\, Director\, KI Clinical Investigator Program\, David H. Koch Professor of Science\, Professor of Biology and Biological Engineering
URL:https://www.masslifesciences.com/event/with-in-sight-webinar-a-foot-in-both-worlds/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210617T040000
DTEND;TZID=America/New_York:20210617T173000
DTSTAMP:20260509T105131
CREATED:20210527T143921Z
LAST-MODIFIED:20210527T143921Z
UID:13973-1623902400-1623951000@www.masslifesciences.com
SUMMARY:FOUNDERS CIRCLE: HOW TO RELOCATE YOUR EARLY-STAGE BIOTECH
DESCRIPTION:Your science is promising and your company is growing. Now is the time to envision your future workplace and consider making some moves. The real estate market can be frustrating\, and life science companies have special operational needs and regulations\, and financial limitations. This forum will explore real-life examples of successful and unsuccessful moves\, providing practical strategies to overcome the common pitfalls that complicate the relocation process. Facilitated by Explora BioLabs CEO\, Nathaniel “Sandy” Paige\, as well as other top experts in life science real estate who will discuss: \n-When and how to find your next space\n-Upfront work: needs analysis\, financial analysis\, market analysis\n-Tapping into City resources\n-Negotiating the terms of your lease\n-Realistic expectations for timelines and budget
URL:https://www.masslifesciences.com/event/founders-circle-how-to-relocate-your-early-stage-biotech/
LOCATION:Online\, online
ORGANIZER;CN="LaunchBio":MAILTO:joan@launchbio.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210617T090000
DTEND;TZID=America/New_York:20210617T120000
DTSTAMP:20260509T105131
CREATED:20210423T202219Z
LAST-MODIFIED:20210423T202219Z
UID:13794-1623920400-1623931200@www.masslifesciences.com
SUMMARY:2021 CAPCaT Big Company/Little Company Showcase
DESCRIPTION:See 9 breakthrough point-of-care innovations and learn about strategic partnership and grant opportunities that can accelerate YOUR startup. \nFor the second straight year\, The Center for Advancing Point of Care Technologies (CAPCaT) in Heart\, Lung\, Blood\, and Sleep Disorders is pleased to present this high-energy\, high-value event for life sciences startups. Join M2D2 and open the doors to big company/little company strategic partnerships and grant funding opportunities. \nKEYNOTE SPEAKER: Bruce J. Tromberg\, PhD\nDr. Tromberg is the Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at the National Institutes of Health (NIH). He oversees a portfolio of research programs focused on developing\, translating\, and commercializing engineering\, physical science\, and computational technologies in Biology and Medicine.
URL:https://www.masslifesciences.com/event/2021-capcat-big-company-little-company-showcase/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210617T090000
DTEND;TZID=America/New_York:20210617T120000
DTSTAMP:20260509T105131
CREATED:20210511T202804Z
LAST-MODIFIED:20210511T202804Z
UID:13818-1623920400-1623931200@www.masslifesciences.com
SUMMARY:2021 CAPCaT Big Company/Little Company Showcase
DESCRIPTION:For the second straight year\, The Center for Advancing Point of Care Technologies (CAPCaT) in Heart\, Lung\, Blood\, and Sleep Disorders is pleased to present this high-energy\, high-value event for life sciences startups. Join us and open the doors to big company/little company strategic partnerships and grant funding opportunities. \nThe Agenda: \nI. Live pitch presentations to our panel of influential strategic and venture capital investors from 9 startups that received grant funding from CAPCaT in 2020: \nCardio Sounds – Device to provide heart and lung predictive clinical intelligence\nCase Western University – Anemia and hemoglobin test\nCognita Labs – CareCOPD precision care platform\nDaxor Corporation – Smart POC heart failure diuretic dosing\nEmerald Innovations – Remote monitoring solution for breathing\, sleep\, mobility\nGE Research – Bedside EIT Lung V/Q scanning\nLeuko Labs 2018 M2D2 $200K Challenge Winner – Non-invasive device to monitor and assess neutrophil levels\nNYU – RELAXaHEAD for Migraine+Sleep\nUSC – Coagulation Companion for Kids\nII. A panel presentation specifically aimed at preparing startups for strategic\, “big company/little company” partnerships. These industry influencers will share real examples and explain the how\, what\, why\, when\, and where of strategic partnerships—and you’re encouraged to participate via our online Q&A portal. \nIII. A presentation on small business funding opportunities and business programming available from the NIH.
URL:https://www.masslifesciences.com/event/2021-capcat-big-company-little-company-showcase-2/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210618
DTEND;VALUE=DATE:20210619
DTSTAMP:20260509T105131
CREATED:20210423T202149Z
LAST-MODIFIED:20210423T202149Z
UID:13795-1623974400-1624060799@www.masslifesciences.com
SUMMARY:VISTA: A New Immune Checkpoint in Cancer\, Autoimmunity and Beyond
DESCRIPTION:Virtual symposium June 18\, 2021. Hosted by Randolph Noelle\, Ph.D. and Padmanee Sharma\, M.D.\, Ph.D. \nSymposium Agenda \nVISTA function across multiple immune lineages in the normal immune system\nVISTA regulation of the tumor microenvironment in human cancer\nDiscovery of anti-VISTA antibodies\nClinical development of anti-VISTA antibodies for cancer immunotherapy\nVISTA counterreceptors \nOrganized by Curis\, Inc.
URL:https://www.masslifesciences.com/event/vista-a-new-immune-checkpoint-in-cancer-autoimmunity-and-beyond/
LOCATION:Online\, online
ORGANIZER;CN="Curis%2C Inc.":MAILTO:info@curis.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210622T110000
DTEND;TZID=America/New_York:20210622T123000
DTSTAMP:20260509T105131
CREATED:20210621T200823Z
LAST-MODIFIED:20210621T200823Z
UID:14013-1624359600-1624365000@www.masslifesciences.com
SUMMARY:Digital Therapeutics and the Future of Medicine
DESCRIPTION:With healthcare becoming more digital\, especially over the past year\, innovators are continuing to demonstrate the power of these potential solutions. However\, despite the constant growth in the last decade and the surge in innovations in the past year\, there are still significant challenges in the path to success for these solutions. \nJoin Johnson & Johnson Innovation – JLABS on June 22nd as they welcome experts in the space to discuss the opportunities and challenges of potential digital solutions from a variety of perspectives\, and how large players in the ecosystem are looking towards the future.
URL:https://www.masslifesciences.com/event/digital-therapeutics-and-the-future-of-medicine/
LOCATION:Online\, online
ORGANIZER;CN="Johnson & Johnson Innovation":MAILTO:clee22@its.jnj.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210623T110000
DTEND;TZID=America/New_York:20210623T120000
DTSTAMP:20260509T105131
CREATED:20210621T200807Z
LAST-MODIFIED:20210621T200807Z
UID:14014-1624446000-1624449600@www.masslifesciences.com
SUMMARY:The Entrepreneurial Way: Veterans Lead in Business & Beyond
DESCRIPTION:Join Johnson & Johnson Innovation on June 23rd for a conversation with leaders from the Johnson & Johnson Family of Companies\, Bunker Labs\, and other experts in the field to discuss the state of Veteran entrepreneurship and the potential impact on healthcare and beyond. \nWe’ll also share details about the Veterans Lead QuickFire Challenge series which is offering grant funding and mentorship opportunities for Veteran entrepreneurs in health care.
URL:https://www.masslifesciences.com/event/the-entrepreneurial-way-veterans-lead-in-business-beyond/
LOCATION:Virtual Event
ORGANIZER;CN="Johnson & Johnson Innovation":MAILTO:clee22@its.jnj.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210623T160000
DTEND;TZID=America/New_York:20210623T190000
DTSTAMP:20260509T105131
CREATED:20210621T200258Z
LAST-MODIFIED:20210621T200258Z
UID:14050-1624464000-1624474800@www.masslifesciences.com
SUMMARY:Venture Capital 101
DESCRIPTION:If you are interested in learning more about how VC investing works\, what their process is for engaging with a life science startup\, and how they manage their portfolios; then you will not want to miss our next event. Please join us on June 23rd from 4-5PM EDT for a talk with Riley Rodgers from Valia Ventures as he explains the ins and outs of VC investing followed by open networking from 5-7PM EDT via the Grapevine Network. \nParticipants are welcome to join the event at any point of time. The event is subject to run later than the posted end time as the room will stay open as long as people are actively engaged within the chat room. \n***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform.
URL:https://www.masslifesciences.com/event/venture-capital-101/
LOCATION:Online\, online
ORGANIZER;CN="BioXchange":MAILTO:bioxchange.boston@gmail.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210624T123000
DTEND;TZID=America/New_York:20210624T133000
DTSTAMP:20260509T105131
CREATED:20210621T200314Z
LAST-MODIFIED:20210621T200344Z
UID:14049-1624537800-1624541400@www.masslifesciences.com
SUMMARY:BARDA Mask Innovation Challenge Awards Ceremony
DESCRIPTION:The Biomedical Advanced Research & Development Authority’s Division of Research\, Innovation\, & Ventures (BARDA DRIVe)\, in partnership with the National Institute for Occupational Safety and Health (NIOSH)\, is proud to present the Awards Ceremony for the “Mask Innovation Challenge: Building Tomorrow’s Mask.” \nThis event will celebrate our 10 Phase 1 finalist teams. They’ve all been working tirelessly to answer the PPE challenge of the pandemic era: Re-imagining and creating the mask of the future. \nWe are proud to announce these winners and highlight our partners and supporters in BARDA’s first-ever Challenge Competition. See you there!
URL:https://www.masslifesciences.com/event/barda-mask-innovation-challenge-awards-ceremony/
LOCATION:Online\, online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210630T090000
DTEND;TZID=America/New_York:20210630T113000
DTSTAMP:20260509T105131
CREATED:20210621T200554Z
LAST-MODIFIED:20210621T200727Z
UID:14015-1625043600-1625052600@www.masslifesciences.com
SUMMARY:Neuroimmunology: Potential for Novel Therapeutics for CNS Disorders
DESCRIPTION:On June 30th \, Johnson & Johnson Innovation will host a virtual scientific event on state-of-the-art developments in neuroimmunology\, bringing together entrepreneurs\, start-ups\, researchers\, and scientists from across Europe and beyond. Learn more and register today
URL:https://www.masslifesciences.com/event/neuroimmunology-potential-for-novel-therapeutics-for-cns-disorders/
LOCATION:Online\, online
ORGANIZER;CN="Johnson & Johnson Innovation":MAILTO:clee22@its.jnj.com
END:VEVENT
END:VCALENDAR